Literature DB >> 32054673

Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis.

Robin Alexandra Ducas1,2, David A Javier2, Rohan D'Souza3, Candice K Silversides2,4, Wendy Tsang5.   

Abstract

OBJECTIVE: To perform a systematic review and meta-analysis of maternal/fetal outcomes in pregnant women with moderate/severe native valvular heart disease (VHD) from medium/higher Human Development Index (HDI) countries.
METHODS: OvidSP platform databases were searched (1985-January 2019) to identify studies reporting pregnancy outcomes in women with moderate/severe VHD. The primary maternal outcome was maternal mortality. The primary fetal/neonatal outcome was stillbirth and neonatal death. Pooled incidences and 95% confidence intervals (CI) of maternal/fetal outcomes could only be calculated from studies involving mitral stenosis (MS) or aortic stenosis (AS).
RESULTS: Twelve studies on 646 pregnancies were included. Pregnant women with severe MS had mortality rates of 3% (95% CI, 0% to 6%), pulmonary oedema 37% (23%-51%) and new/recurrent arrhythmias 16% (1%-25%). Their stillbirth, neonatal death and preterm birth rates were 4% (1%-7%), 2% (0%-4%), and 18% (7%-29%), respectively. Women with moderate MS had mortality rates of 1%(0%-2%), pulmonary oedema 18% (2%-33%), new/recurrent arrhythmias 5% (1%-9%), stillbirth 2% (1%-4%) and preterm birth 10%(2%-17%).Pregnant women with severe AS had a risk of mortality of 2% (0%-5%), pulmonary oedema 9% (2%-15%), and new/recurrent arrhythmias 4% (0%-7%). Their stillbirth, neonatal death and preterm birth rates were 2% (0%-5%), 3% (0%-6%) and 14%(4%-24%), respectively. No maternal/neonatal deaths were reported in moderate AS, however women experienced pulmonary oedema (8%; 0%-20%), new/recurrent arrhythmias (2%; 0%-5%), and preterm birth (13%; 6%-20%).
CONCLUSIONS: Women with moderate/severe MS and AS are at risk for adverse maternal and fetal/neonatal outcomes. They should receive preconception counseling and pregnancy care by teams with pregnancy and heart disease experience. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  meta-analysis; pregnancy; valvular heart disease

Year:  2020        PMID: 32054673     DOI: 10.1136/heartjnl-2019-315859

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

1.  Cardiovascular and Obstetric Delivery Complications in Pregnant Women With Valvular Heart Disease.

Authors:  Anum S Minhas; Faisal Rahman; Nicole Gavin; Ari Cedars; Arthur Jason Vaught; Sammy Zakaria; Jon Resar; Stefano Schena; Steven Schulman; Di Zhao; Allison G Hays; Erin D Michos
Journal:  Am J Cardiol       Date:  2021-08-24       Impact factor: 2.778

Review 2.  Anaesthetic considerations and anticoagulation in pregnant patients with mechanical heart valves.

Authors:  K Bhatia; N Shehata; R D'Souza
Journal:  BJA Educ       Date:  2022-03-24

3.  Maternal and Fetal Outcomes Following Percutaneous Transluminal Mitral Commissurotomy in Pregnant Women with Critical Mitral Stenosis: An Experience of a Tertiary Care Center from Northern India.

Authors:  Rajesh Vijayvergiya; Vanita Suri; Pooja Sikka; Ganesh Kasinadhuni; Ankush Gupta; Navjyot Kaur; Sujata Siwatch; Neelam Aggarwal; Seema Chopra
Journal:  Anatol J Cardiol       Date:  2022-07       Impact factor: 1.475

Review 4.  Role of MicroRNAs in Cardiac Disease with Stroke in Pregnancy.

Authors:  Umme Salma; Ahmed Baker A Alshaikh; Muhannad Faleh Alanazi; Basil Mohammed Alomair; Mubarak Alruwaili; Raed Alruwaili
Journal:  Oxid Med Cell Longev       Date:  2022-09-12       Impact factor: 7.310

Review 5.  Peripartum considerations for women with cardiac disease.

Authors:  Hanna Hussey; Patrick Hussey; Marie-Louise Meng
Journal:  Curr Opin Anaesthesiol       Date:  2021-06-01       Impact factor: 2.733

6.  Long-term survival in patients with isolated pulmonary valve stenosis: a not so benign disease?

Authors:  Kristofer Skoglund; Annika Rosengren; Georgios Lappas; Maria Fedchenko; Zacharias Mandalenakis
Journal:  Open Heart       Date:  2021-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.